BR112014012739A2 - composições e métodos para o tratamento do vírus da hepatite c - Google Patents

composições e métodos para o tratamento do vírus da hepatite c

Info

Publication number
BR112014012739A2
BR112014012739A2 BR112014012739A BR112014012739A BR112014012739A2 BR 112014012739 A2 BR112014012739 A2 BR 112014012739A2 BR 112014012739 A BR112014012739 A BR 112014012739A BR 112014012739 A BR112014012739 A BR 112014012739A BR 112014012739 A2 BR112014012739 A2 BR 112014012739A2
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
effective amount
methods
compositions
Prior art date
Application number
BR112014012739A
Other languages
English (en)
Other versions
BR112014012739A8 (pt
Inventor
S Ray Adrian
j reynolds Charles
M Hebner Christy
G Cleary Darryl
Stefanidis Dimitrios
Mo Hongmei
Jean Casteel Melissa
Michelle Berrey Miriam
Oliyai Reza
G Hindes Robert
Pakdaman Rowchanak
Zia Vahid
T Symonds William
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of BR112014012739A2 publication Critical patent/BR112014012739A2/pt
Publication of BR112014012739A8 publication Critical patent/BR112014012739A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

composições e métodos para o tratamento do vírus da hepatite c aqui divulgados são uma composição e forma de dosagem unitária para o tratamento de infecção pelo vírus da hepatite c (vhc) compreendendo gs-7977 e, pelo menos, um excipiente farmaceuticamente aceitável, bem como métodos para fazer a referida composição e forma de dosagem unitária. é também aqui descrito um método de tratamento de um indivíduo, de preferência um ser humano, infectado com o vírus da hepatite c, o referido método compreendendo a administração ao indivíduo, por um período de tempo, uma quantidade eficaz de gm-7977 e uma quantidade eficaz de ribavirina. em um aspecto, o método compreende a administração ao indivíduo de um regime de tratamento livre de interferon que compreende uma quantidade eficaz de gm-7977 e uma quantidade eficaz de ribavirina. em um aspecto particular, o método é suficiente para produzir uma quantidade não detectável de rna de vhc no indivíduo durante pelo menos 12 semanas após o final do período de tempo.
BR112014012739A 2011-11-29 2012-11-27 composições e métodos para o tratamento do vírus da hepatite c BR112014012739A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus
PCT/US2012/066605 WO2013082003A1 (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Publications (2)

Publication Number Publication Date
BR112014012739A2 true BR112014012739A2 (pt) 2017-06-13
BR112014012739A8 BR112014012739A8 (pt) 2017-06-20

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012739A BR112014012739A8 (pt) 2011-11-29 2012-11-27 composições e métodos para o tratamento do vírus da hepatite c

Country Status (22)

Country Link
EP (2) EP2785340B1 (pt)
JP (2) JP5899327B2 (pt)
KR (1) KR101560994B1 (pt)
CN (1) CN104039319B (pt)
AR (1) AR089578A1 (pt)
AU (1) AU2012346217B2 (pt)
BR (1) BR112014012739A8 (pt)
CA (1) CA2856529C (pt)
CO (1) CO6970603A2 (pt)
EA (1) EA027296B1 (pt)
EC (1) ECSP14005678A (pt)
ES (1) ES2817886T3 (pt)
HK (1) HK1202268A1 (pt)
MD (1) MD4430C1 (pt)
MX (1) MX2014006373A (pt)
PE (1) PE20141296A1 (pt)
PH (1) PH12014501133B1 (pt)
SG (1) SG11201402609RA (pt)
TW (1) TWI566773B (pt)
UY (1) UY34474A (pt)
WO (1) WO2013082003A1 (pt)
ZA (1) ZA201404061B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3113762A1 (en) * 2014-03-05 2017-01-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
CA2988393C (en) * 2014-06-13 2023-08-22 Ratiopharm Gmbh Solid state forms of sofosbuvir
EP2959888A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
WO2015197518A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
US20170128482A1 (en) * 2014-06-23 2017-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016055576A1 (en) * 2014-10-08 2016-04-14 Sandoz Ag High drug load tablets comprising sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
EP3500584A1 (en) 2016-08-19 2019-06-26 Sandoz AG Sofosbuvir derivatives for the treatment of hepatitis c
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
EP2125113A2 (en) * 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
AU2009316472B2 (en) * 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
US8618076B2 (en) * 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
JP2014533733A (ja) 2014-12-15
JP5899327B2 (ja) 2016-04-06
CA2856529A1 (en) 2013-06-06
AU2012346217A1 (en) 2014-06-19
CO6970603A2 (es) 2014-06-13
PH12014501133A1 (en) 2014-09-01
AU2012346217B2 (en) 2016-02-04
NZ625532A (en) 2016-07-29
ES2817886T3 (es) 2021-04-08
TWI566773B (zh) 2017-01-21
PH12014501133B1 (en) 2014-09-01
MX2014006373A (es) 2014-07-22
ZA201404061B (en) 2016-09-28
SG11201402609RA (en) 2014-06-27
JP2016053096A (ja) 2016-04-14
KR101560994B1 (ko) 2015-10-15
TW201325599A (zh) 2013-07-01
EA027296B1 (ru) 2017-07-31
CN104039319A (zh) 2014-09-10
EA201490903A1 (ru) 2014-11-28
CA2856529C (en) 2018-03-06
EP2785340A1 (en) 2014-10-08
CN104039319B (zh) 2017-12-29
HK1202268A1 (en) 2015-09-25
BR112014012739A8 (pt) 2017-06-20
MD4430B1 (ro) 2016-08-31
EP3777867A1 (en) 2021-02-17
UY34474A (es) 2013-06-28
EP2785340B1 (en) 2020-07-15
WO2013082003A1 (en) 2013-06-06
AR089578A1 (es) 2014-09-03
MD20140058A2 (en) 2014-11-30
PE20141296A1 (es) 2014-10-08
KR20140108645A (ko) 2014-09-12
ECSP14005678A (es) 2015-12-31
MD4430C1 (ro) 2017-03-31

Similar Documents

Publication Publication Date Title
BR112014012739A2 (pt) composições e métodos para o tratamento do vírus da hepatite c
BR112014010295A2 (pt) métodos e composições para o tratamento de vírus de hepatite c
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
TN2012000135A1 (en) Cyclic peptide inhibitors of hepatitis c virus replication
MY160130A (en) Hepatitis c virus inhibitors
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112015010461A2 (pt) usos alternativos para efetores da reunião do hbv
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL